China Probes Against Foreign Pharma are 'Unfair'


Sep 05, 2013

Foreign companies believe they are unfairly being singled out for scrutiny in bribery and pricing investigations, the biggest European business group in China said Thursday.

The comments by officials of the European Chamber of Commerce in China follow announcements about fines imposed on dairy suppliers over pricing issues and an investigation into possibly bribery by employees of drug manufacturers GlaxoSmithKline and Sanofi.

"What I feel a little bit unfair, the foreign companies that are most serious about SOPs have been the most investigated and the most discriminated," said the president of the chamber's pharmaceutical working group, Bruno Gensberger. "To my knowledge, today no Chinese company has been investigated." Read more
Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments